Wave Life Sciences to Webcast Conference Call of Third Quarter 2022 Financial Results on November 10, 2022

Rhea-AI Summary

Wave Life Sciences (Nasdaq: WVE) announced a conference call scheduled for 8:30 a.m. ET on November 10, 2022, to discuss its Q3 2022 financial results and provide a business update. The call will be accessible via the company’s investor relations webpage. Wave Life Sciences is a clinical-stage genetic medicines company focused on developing treatments for severe diseases using its proprietary PRISM platform for drug development. The archived call will also be available post-event.

Positive

• The upcoming conference call indicates transparency and engagement with investors.
• Wave Life Sciences' focus on genetic medicines positions it in a niche with significant growth potential.

Negative

• No specific financial metrics or growth indicators were mentioned in the PR.
• No updates on ongoing clinical trials or product pipelines were provided.

CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference call at 8:30 a.m. ET on Thursday, November 10, 2022, to discuss the company’s third quarter 2022 financial results and provide a business update.

The webcast of the conference call may be accessed by visiting “Events” at the investor relations section of the Wave Life Sciences corporate website: ir.wavelifesciences.com.

Participants planning to ask a question during the Q&A portion of the live call can join the webcast at the following audio conferencing link: https://register.vevent.com/register/BI3c61006b6de34cd6a3924918ba54e58f.

Following the conference call, an archived version of the call will be available on the website.

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci.

Investor Contact:
Kate Rausch
617-949-4827
krausch@wavelifesci.com

Media Contact:
Alicia Suter
617-949-4817
asuter@wavelifesci.com

FAQ

When will Wave Life Sciences announce its Q3 2022 financial results?

Wave Life Sciences will announce its Q3 2022 financial results on November 10, 2022.

How can I access the Wave Life Sciences conference call?

The conference call can be accessed through the investor relations section of Wave Life Sciences' website.

What is the purpose of the upcoming Wave Life Sciences conference call?

The purpose of the conference call is to discuss Q3 2022 financial results and provide a business update.

What is Wave Life Sciences known for?

Wave Life Sciences is known for its clinical-stage work in genetic medicines and its proprietary PRISM platform.